Targeting DUBs to degrade oncogenic proteins
Anjali Cremer, Kimberly Stegmaier
Abstract
Targeted protein degradation has emerged as a strategy in cancer therapy. Yang et al. discovered that HBX19818, an inhibitor of the deubiquitinase (DUB) USP10, leads to the dual degradation of spleen tyrosine kinase (SYK) and FLT3, resulting in death of AML cells.
Topics & Concepts
Deubiquitinating enzymeSykCancer researchTargeted therapyTyrosine kinaseBiologyCancerUbiquitinProtein degradationBruton's tyrosine kinaseCell biologySignal transductionGeneBiochemistryGeneticsProtein Degradation and InhibitorsUbiquitin and proteasome pathwaysHistone Deacetylase Inhibitors Research